Biography
Maureen Rutten-van Mölken is Professor of Economic Evaluation of Innovations for Health at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. She is also the Scientific Director of the Institute for Medical Technology Assessment (IMTA).
She teaches “Health Technology Assessment” and “Pharmaceutical Pricing and Market Access” in the Master-program Health Economics Policy and Law at Erasmus University Rotterdam.
Her expertise includes economic evaluation studies, either alongside clinical trials or using probabilistic decision-analytic modeling, and outcomes research. She worked in many disease areas, including respiratory diseases (COPD, asthma), rheumatology, diabetes, cardiovascular disease, and Pompe disease. She has a special interest in the cost-effectiveness and the financing and payment of complex multi-faceted interventions that involve system-level changes like integrated care programs, disease management programs, hospital at home programs, outpatient rehabilitation programs, etc. She also has an interest in the health economics of personalized medicine.
She has almost 30 years of experience and has been leading many applied economic evaluations and HTA methods-studies leading to high-level publications. She is the coordinator of SELFIE, a Horizon2020 project on integrated care in multi-morbidity, and contributes to Horizon2020 project HEcoPerMed that develops guidance on health economic modeling, and financing and payment strategies for personalized medicine.
She was trained as a health scientist and had additional training in health economics and epidemiology. She obtained an MSc in Health Care Policy and Management at Maastricht University (1988), and a PhD in Health Economics, also at Maastricht University (1994). She joined iMTA as a Senior Researcher in 1996. Previously, she was an Assistant Professor in Health Economics and Medical Technology Assessment at the Department of Health Economics of the University of Maastricht.
Erasmus School of Health Policy & Management
- m.rutten@eshpm.eur.nl
More information
Work
- Rhiannon Green, Michael Baldwin, Nick Pooley, Kate Misso, Maureen PMH Rutten van Mölken, Nina Patel & Marlies S. Wijsenbeek (2024) - The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis - Respiratory Research, 25 (1) - doi: 10.1186/s12931-024-02897-w - [link]
- Elise Van Mulligen, Maureen Rutten-Van Mölken & Annette Van Der Helm-Van Mil (2024) - Early identification of rheumatoid arthritis: does it induce treatment-related cost savings? - Annals of the rheumatic diseases - doi: 10.1136/ard-2024-225746 - [link]
- Bart Jan Boverhof, W. Ken Redekop, Jacob J. Visser, Carin A. Uyl-de Groot & Maureen P.M.H. Rutten-van Mölken (2024) - Broadening the HTA of medical AI: A review of the literature to inform a tailored approach - Health Policy and Technology, 13 (2) - doi: 10.1016/j.hlpt.2024.100868 - [link]
- Liz J.A. Cuperus, Cathelijne M. van Zelst, Huib A.M. Kerstjens, Rudi W. Hendriks, Maureen P.M.H. Rutten-van Molken, Jacqueline B. Muilwijk-Kroes, Gert Jan Braunstahl & Johannes C.C.M. in ’t Veen (2024) - Measuring burden of disease in both asthma and COPD by merging the ACQ and CCQ: less is more? - npj Primary Care Respiratory Medicine, 34 (1) - doi: 10.1038/s41533-024-00364-z - [link]
- Hamraz Mokri, Pieter van Baal & Maureen Rutten-van Mölken (2024) - The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries - European Journal of Health Economics - doi: 10.1007/s10198-024-01690-2 - [link]
- Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, Simone A Huygens, Winand N.M. Dinjens & Maureen Rutten van Mölken (2024) - Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands - Molecular Diagnosis and Therapy, 28 (3), 319-328 - doi: 10.1007/s40291-024-00704-2 - [link]
- Hamraz Mokri, Pascal R.D. Clephas, Rudolf A. de Boer, Pieter van Baal, Jasper J. Brugts & Maureen P.M.H. Rutten-van Mölken (2024) - Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands - European Journal of Heart Failure, 26 (5), 1189-1198 - doi: 10.1002/ejhf.3213 - [link]
- Jan A. Witte, Erwin Birnie, Gert-Jan Braunstahl, Edmée van den Akker, Walter J.M. van Litsenburg, Niels H. Chavannes, Maureen van Molken & Johannes C.C.M. in ’t Veen (2023) - Implementing integrated care guidelines in asthma and COPD: It ain't easy! - Heliyon, 9 (11), e21540 - doi: 10.1016/j.heliyon.2023.e21540 - [link]
- Maureen van Molken, Matthijs Versteegh, Balázs Nagy & Sarah Wordsworth (2023) - HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead - Personalized Medicine, 20 (4), 299-303 - doi: 10.2217/pme-2022-0074
- Chiara Whichello, Ian Smith, Jorien Veldwijk, G. Ardine de Wit, Maureen P.M.H. Rutten- van Molken & Esther W. de Bekker-Grob (2023) - Discrete choice experiment versus swing-weighting: A head-to-head comparison of diabetic patient preferences for glucose-monitoring devices - PLoS ONE, 18 (7 JULY) - doi: 10.1371/journal.pone.0283926 - [link]
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
Master HEPL-HE 2024-2025
- Year
- 2024
- Course Code
- GWMTTHEPL
Health Technology Assessment
- Year Level
- master, master, master
- Year
- 2024
- Course Code
- GW4546M
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4585M
Pharmaceutical Pricing and Market Access
- Year Level
- master, master, master, master
- Year
- 2024
- Course Code
- GW4575M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M